Document Detail


Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy.
MedLine Citation:
PMID:  15617585     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the safety profile of platelet glycoprotein IIb/IIIa inhibitors administered as adjunctive therapy to patients with large-vessel occlusion and acute ischemic stroke refractory to pharmacological thrombolysis with recombinant tissue plasminogen activator (rtPA) and mechanical disruption, balloon angioplasty, or both.
METHODS: Twenty-one patients (mean age, 62 yr; range, 29-88 yr) met the following criteria: 1) large-vessel occlusion and acute ischemic stroke syndrome at presentation, 2) failure to recanalize after administration of rtPA (intra-arterial and/or intravenous) with or without mechanical thrombolysis, and 3) subsequent treatment with IIb/IIIa inhibitors (intra-arterial or intravenous).
RESULTS: Eleven patients had ischemia in the dominant hemisphere, 8 in the vertebrobasilar system, and 2 in the nondominant hemisphere. Twelve patients received intravenous rtPA without significant improvement; 9 patients were not candidates for intravenous rtPA. All patients received intra-arterial rtPA. The IIb/IIIa inhibitors were administered intravenously in 3 patients, intra-arterially in 16, and both intravenously and intra-arterially in 2. Balloon angioplasty was performed in 18 patients. Complete or partial recanalization was achieved in 17 of the 21 patients. After thrombolysis, 15 improved clinically. Three patients (14%) sustained an asymptomatic intracerebral hemorrhage after thrombolytic therapy. No patient was clinically worse after intervention. At last follow-up (mean, 8.5 mo), 13 patients were functionally independent (modified Rankin score, 0-3) and 8 were disabled or dead.
CONCLUSION: IIb/IIIa inhibitors are an alternative for achieving recanalization. The risk of hemorrhage may be low. As part of an escalating protocol that includes pharmacological and mechanical thrombolysis, IIb/IIIa inhibitors may improve clinical outcomes.
Authors:
Vivek R Deshmukh; David J Fiorella; Felipe C Albuquerque; James Frey; Murray Flaster; Robert C Wallace; Robert F Spetzler; Cameron G McDougall
Related Documents :
17309795 - Socially assistive robotics for post-stroke rehabilitation.
3763815 - Heat stroke at the mekkah pilgrimage: clinical characteristics and course of 30 patients.
8650505 - Description and validation of a test of motor function and activities in stroke patient...
7570725 - Ischemic stroke events and carotid atherosclerosis. results of the osaka follow-up stud...
16006495 - Patient factors associated with delay in primary care among patients with head and neck...
21523525 - Limitations of threshold-based brain oxygen monitoring for seizure detection.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurosurgery     Volume:  56     ISSN:  1524-4040     ISO Abbreviation:  Neurosurgery     Publication Date:  2005  
Date Detail:
Created Date:  2004-12-24     Completed Date:  2006-05-30     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  7802914     Medline TA:  Neurosurgery     Country:  United States    
Other Details:
Languages:  eng     Pagination:  46-54; discussion 54-5     Citation Subset:  IM    
Affiliation:
Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use*
Brain Ischemia / complications,  drug therapy*
Chemotherapy, Adjuvant
Female
Humans
Immunoglobulin Fab Fragments / therapeutic use*
Male
Middle Aged
Peptides / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Prospective Studies
Stroke / complications,  drug therapy*
Thrombolytic Therapy*
Tyrosine / analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Peptides; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/eptifibatide; 144494-65-5/tirofiban; 55520-40-6/Tyrosine; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rotational vertebrobasilar ischemia: hemodynamic assessment and surgical treatment.
Next Document:  Radiosurgery for basal ganglia, internal capsule, and thalamus arteriovenous malformation: clinical ...